Endo's $10M opioid deal could help other drugmakers 'out of the woods': analysts

Endo’s $10 million opioid deal with two Ohio counties Tuesday may have appeared small in scope to some, but could the bellwether agreement spell a sigh of relief for the industry on the whole? Investors and analysts seem to think so.